Science

Neeraj Agarwal: Patient-reported QOL results in phase 3 TALAPRO-2 trial

Neeraj Agarwal/poet-calgary.ca

Apr 4, 2025, 10:16

Neeraj Agarwal: Patient-reported QOL results in phase 3 TALAPRO-2 trial

Shilpa Gupta, Director of Genitourinary Oncology and a Professor of Medicine at Cleveland Clinic, reshared a post by Neeraj Agarwal, Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, on X, adding:

“Double congratulations Neeraj Agarwal, Arun Azad, Karim Fizazi and entire TALAPRO-2 team.

Great to see this QOL data from TALAPRO-2 & very reassuring to see QOL not compromised with this regimen for patients.”

Quoting Neeraj Agarwal‘s post:

“Just in Two The Lancet Oncology papers on patient-reported QOL results in ph3 TALAPRO-2 trial in all-comer & HRR deficient mCRPC Prostate Cancer patients. Improved OS without compromising QOL.”

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.

Authors: Nobuaki Matsubara, et al.

Neeraj Agarwal: Patient-reported QOL results in phase 3 TALAPRO-2 trial

Arun Azad cancer Cancer research Cleveland Clinic fight against cancer Genitourinary Oncology Global fight against cancer Huntsman Cancer Institute Karim Fizazi Neeraj Agarwal OncoDaily Oncology prostate cancer Shilpa Gupta TALAPRO-2 trial The Lancet Oncology

OncoBillionaires of 2025: The Titans Behind the Cancer Revolution

Val Kilmer Dies at 65: The Actor Who Fought Throat Cancer and Inspired Generations

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer